Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ01075 in advanced solid tumors
NCT05470933Phase 1Terminated
- Sponsor
- Suzhou Junjing BioSciences
- Start
- Aug 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of WJ01075 in solid tumor (advanced stage), sponsored by Suzhou Junjing BioSciences. Primary endpoints: Dose Limited Toxicity at 3 years, Adverse Events at 3 years and 3 more. Started Aug 2022; status: terminated.
02
Drugs
WJ01075
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05470933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470933.